Bafna Pharmaceuticals Limited has submitted its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 to stock exchanges, confirming adherence to dematerialisation requirements for the quarter ended March 31, 2026.

Regulatory Compliance Filing

The pharmaceutical company filed the certificate under Regulation 74(5) of SEBI Depositories Regulations with both BSE Limited and National Stock Exchange of India Limited on April 13, 2026. Company Secretary and Compliance Officer Mohanachandran A signed the submission digitally, ensuring proper documentation of the regulatory requirement.

Registrar Confirmation

Cameo Corporate Services Limited, serving as the company's Registrar and Share Transfer Agent, issued the compliance certificate on April 6, 2026. The registrar confirmed that securities received from depository participants for dematerialisation during the quarter were properly processed and confirmed to depositories within stipulated timeframes.

Dematerialisation Process Compliance

The certificate confirms that all security certificates received for dematerialisation were properly mutilated and cancelled after due verification by depository participants. The registrar verified that depositories' names were substituted in the register of members as registered owners within the stipulated time limits under the captioned regulations.

Key compliance confirmations include:

• Securities received from depository participants were confirmed to depositories
• Security certificates were mutilated and cancelled after proper verification
• Depository names were substituted in member registers within required timeframes
• All securities remain listed on stock exchanges where earlier issued securities are traded

Corporate Information

Bafna Pharmaceuticals Limited operates from its registered office at Bafna Towers, No.299, Thambu Chetty Street, Chennai. The company maintains its corporate identification number as L24294TN1995PLC030698 and continues its regulatory compliance obligations as a publicly listed pharmaceutical company.

Bafna Pharmaceuticals Limited's Board of Directors has approved the appointment of new Internal and Cost Auditors for the Financial Year 2026-2027. The board meeting held on March 27, 2026, addressed key auditing requirements as part of the company's regulatory compliance framework.

Board Meeting Outcomes

The board meeting, which commenced at 12:30 PM and concluded at 1:00 PM on March 27, 2026, resulted in two significant appointments:

Internal Auditor Appointment

The board appointed M/s. K.S. Rao & Co., Chartered Accountants, Chennai as the Internal Auditor for Financial Year 2026-2027. The firm brings substantial expertise to the role:

M/s. K.S. Rao & Co. is described as a reputed audit firm specializing in Statutory Audit, Internal Audit, Systems Audit, Management Audit, and other related audit and advisory services. The firm has extensive experience helping industries across multiple domains with their processes.

Cost Auditor Appointment

Simultaneously, the board appointed M/s. N. Sivashankaran & Co., Cost Accountants, Chennai as the Cost Auditor for the same financial year period:

The firm is characterized as well-established with extensive experience in cost and management accounting, cost audit, and financial consultancy services.

Regulatory Compliance

The appointments were made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has provided comprehensive disclosures as required under SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. Both appointments indicate no relationships between the appointed firms and the company's directors, ensuring independence in auditing functions.